Search
Arbutus Biopharma Corp
ABUSAdd to Watchlist
4.450USD
-0.110-2.41%
Close 10-02 16:00（ET）
879.05MMarket Cap
5.40P/E TTM
Pre-market 05:32 (ET)4.090USD-0.360-8.09%
Pre-market 05:32 (ET)Arbutus Biopharma Corp (ABUS) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Arbutus Biopharma Corp in the past month.
Strong Buy
1 Strong Buy
0 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
5.500USD+23.60%
ABUS Analyst Recommendation Trends
In the current month, ABUS has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ABUS average Analyst price target in the last month is 5.500.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
1
1
0
0
1
2
2
2
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
2
3
3
3
3
3
ABUS Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ABUS EPS is projected to reach -0.020 in FY2026Q3, following reported EPS of -0.026 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.04
-0.03
-0.02
-0.02
-0.02
Actual
-0.02
0.88
-0.03
--
--
Surprise
+44.20%
+3019.20%
-30.20%
--
--
FAQs
What is Arbutus Biopharma Corp's expected revenue for the next quarter?
Arbutus Biopharma Corp's expected revenue is 1.00M.
What is Arbutus Biopharma Corp's price target?
Analysts forecast that Arbutus Biopharma Corp's price target is USD 5.50, with the highest forecast at USD 5.50 and the lowest forecast at USD 5.50.
How have Arbutus Biopharma CorpABUS's recent earnings per share performed?
The market expectation was USD -0.03, while Arbutus Biopharma CorpABUS's earnings per share (EPS) for the previous quarter was USD 0.88. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for Arbutus Biopharma Corp?
Based on the ratings of Arbutus Biopharma Corp's stock from 1 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.